Axa
LXRX icon

Axa’s Lexicon Pharmaceuticals LXRX Stock Holding History

Axa’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-356,400
Closed -$816K – 1121
2023
Q2 		$816K Hold
356,400
– – ﹤0.01% 871
2023
Q1 		$866K Buy
356,400
+335,500
+1,605% +$769K ﹤0.01% 889
2022
Q4 		$39.9K Sell
20,900
-91,268
-81% -$194K ﹤0.01% 1118
2022
Q3 		$269K Buy
112,168
+91,268
+437% +$253K ﹤0.01% 1061
2022
Q2 		$38.9K Hold
20,900
– – ﹤0.01% 1105
2022
Q1 		$43.7K Sell
20,900
-54,300
-72% -$151K ﹤0.01% 1177
2021
Q4 		$296K Buy
+75,200
New +$365K ﹤0.01% 1090
2021
Q3 		– Sell
-285,500
Closed -$1.31M – 1282
2021
Q2 		$1.31M Sell
285,500
-116,800
-29% -$563K ﹤0.01% 958
2021
Q1 		$2.36M Buy
402,300
+340,100
+547% +$2.35M 0.01% 823
2020
Q4 		$213K Buy
+62,200
New +$119K ﹤0.01% 1166
2020
Q2 		– Sell
-19,300
Closed -$38K – 1272
2020
Q1 		$38K Sell
19,300
-115,402
-86% -$344K ﹤0.01% 1159
2019
Q4 		$559K Buy
134,702
+50,702
+60% +$195K ﹤0.01% 980
2019
Q3 		$253K Sell
84,000
-44,600
-35% -$138K ﹤0.01% 1217
2019
Q2 		$809K Buy
128,600
+72,000
+127% +$431K ﹤0.01% 1008
2019
Q1 		$315K Buy
+56,600
New +$344K ﹤0.01% 1186
2014
Q3 		– Sell
-64,368
Closed -$725K – 1462
2014
Q2 		$725K Sell
64,368
-2,589
-4% -$27.8K ﹤0.01% 1000
2014
Q1 		$811K Buy
66,957
+3,487
+5% +$44.6K ﹤0.01% 971
2013
Q4 		$800K Buy
63,470
+3,157
+5% +$50.2K ﹤0.01% 969
2013
Q3 		$1M Buy
60,313
+12,220
+25% +$205K ﹤0.01% 871
2013
Q2 		$731K Buy
+48,093
New +$731K ﹤0.01% 890

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Axa's LXRX Position: Q3 2023 in Review

Axa sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2023, closing a stake of 356,400 shares — an estimated $816K sold.

Axa first reported a position in LXRX in Q2 2013 and held it in 20 quarters. The position peaked at $2.36M in Q1 2021. 112 funds tracked by Wall St. Rank hold LXRX as of Q3 2023.

  • Axa reported no remaining Lexicon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Axa sold 356,400 Lexicon Pharmaceuticals shares in Q3 2023, an estimated $816K.
  • Axa first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Axa's Lexicon Pharmaceuticals position peaked at $2.36M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.